Camber Announces Two New Product Launches
Camber Pharmaceuticals, one of the industry’s fastest growing generic pharmaceutical companies is pleased to announce the addition of two new products to its rapidly expanding product line.
The new products are as follows:
Benztropine Mesylate Finasteride
– .5mg / 100ct – 1mg/ 30ct and 90ct
– 1mg / 100ct and 1000ct
– 2mg / 100ct and 1000ct
Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products from API manufacturing to finished dosage.
Camber’s parent company Hetero Drugs of Hyderabad, India employs over 300 scientists at 9 API facilities and has a global presence in over 100 countries.
Recent articles
- NACDS TSE 2026 Event Recap
- Camber Specialty Marks First Day 1 Injectable Launch
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio






